Literature DB >> 9091644

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.

M Kawakita1, G S Rao, J K Ritchey, D K Ornstein, M A Hudson, J Tartaglia, E Paoletti, P A Humphrey, T J Harmon, T L Ratliff.   

Abstract

BACKGROUND: Canarypox virus, ALVAC, does not replicate in infected mammalian cells and has potential as a vector for gene therapy in the treatment of cancer.
PURPOSE: Recombinant viruses carrying DNA sequences encoding interleukin 2 (ALVAC-IL-2), interferon gamma (ALVAC-IFN gamma), tumor necrosis factor-alpha (ALVAC-TNF-alpha), or the co-stimulatory molecule B7-1 (ALVAC-B7-1) were investigated as agents for the treatment of a newly defined mouse prostate tumor model.
METHODS: RM-1 mouse prostate cancer cells, which are syngeneic (i.e., same genetic background) to C57BL/6 mice, were used. The expression of foreign gene products in vitro in infected RM-1 cells was measured by immunoprecipitation, bioassay, or flow cytometry. The effects of foreign gene product expression on RM-1 tumor cell growth in C57BL/6 mice were measured after subcutaneous injection (in the back) of 5 x 10(5) uninfected or infected cells; measurements included determinations of time to a measurable tumor size, tumor size as a function of time, and survival. The induction of protective immunity by uninfected and infected RM-1 cells was tested by injection of lethally irradiated (70 Gy) cells and subsequent challenge with uninfected cells. The generation of cytotoxic T cells was monitored by use of a 51Cr release assay. Severe combined immunodeficient (SCID) mice were used to determine whether T or B lymphocytes were involved in ALVAC vector-mediated antitumor responses. Data were analyzed by use of Pearson's modification of the chi-squared test and Kaplan-Meier survival methods. Reported P values are two-sided.
RESULTS: The level of foreign gene product expression in ALVAC-infected RM-1 cells was dependent on the multiplicity of virus infection used; a multiplicity of five viruses per infected cell was chosen for subsequent experiments. RM-1 tumor growth in C57BL/6 mice was not affected by tumor cell expression of IL-2 alone, IFN gamma alone, or B7-1 alone; however, expression of TNF-alpha alone significantly delayed tumor growth at early time points (compared with parental ALVAC-infected tumors, P = .0001 at day 21 and P = .037 at day 28). Tumor cell expression of both TNF-alpha and IL-2 completely inhibited tumor growth in 60%-100% of treated mice. No protection against subsequent tumor challenge was detected in mice previously exposed to RM-1 cells expressing both TNF-alpha and IL-2. Cytotoxic T-lymphocyte activity toward RM-1 cells was not observed in C57BL/6 mice that rejected tumors. Tumor cell expression of TNF-alpha and IL-2 also resulted in tumor growth inhibition in SCID mice.
CONCLUSIONS: RM-1 mouse prostate cancer cells are readily infected by ALVAC vectors, and foreign gene products are efficiently expressed. Inhibition of RM-1 tumor growth by tumor cell expression of TNF-alpha and IL-2 appears to involve nonspecific antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9091644     DOI: 10.1093/jnci/89.6.428

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Transient, nonlethal expression of genes in vertebrate cells by recombinant entomopoxviruses.

Authors:  Y Li; R L Hall; R W Moyer
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.

Authors:  L G Charles; Y C Xie; N P Restifo; B Roessler; M G Sanda
Journal:  World J Urol       Date:  2000-04       Impact factor: 4.226

Review 4.  Considering the potential for gene-based therapy in prostate cancer.

Authors:  Justin R Gregg; Timothy C Thompson
Journal:  Nat Rev Urol       Date:  2021-02-26       Impact factor: 14.432

5.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

Authors:  N P Restifo; D R Surman; H Zheng; P Palese; S A Rosenberg; A García-Sastre
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

Review 7.  Immunotherapy of prostate cancer.

Authors:  S J Freedland; A J Pantuck; J Weider; A Zisman; A S Belldegrun
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 2.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.